Valye reports for unlimited access

SL Science Holding Limited operates as a holding company with its business activities conducted through SL Bio. It specializes in developing next-generation allogeneic cell therapies, focusing on cancer treatments using proprietary Armed-T and Gamma Delta T cell technologies. The company’s Armed-T therapy uses bispecific antibodies to arm T cells without genetic modification, targeting CD-19 for blood cancers. Gamma Delta T cell technology is developed for pancreatic and brain cancer treatments. SL Science’s business model centers on advancing preclinical research, securing regulatory approvals, and forming partnerships with pharmaceutical companies to commercialize its therapies. The company also maintains legacy exosome cosmetic and plant supplement businesses, which it plans to phase out as its cell therapy products mature.

Central Plains Bancshares, Inc. is a Maryland corporation owning Home Federal Savings and Loan Association of Grand Island, operating as Home Federal Bank headquartered in Grand Island, Nebraska. The company completed its IPO in October 2023, raising approximately $41.3 million. It operates primarily in southcentral Nebraska with nine office locations serving counties including Adams, Dawson, Hall, Lancaster, Nuckolls, and Phelps. The company’s business model centers on accepting deposits and investing in a diversified loan portfolio including residential mortgages, commercial real estate, commercial non-real estate, agricultural, and consumer loans. It offers various deposit products and electronic banking services. The loan portfolio as of March 31, 2026 totaled approximately $448 million, with a mix of fixed and adjustable-rate loans and conservative underwriting standards. The company is regulated by the OCC and faces competition from a range of financial institutions and fintech firms in its market area.

Medtronic plc is a leading global medical technology company engaged in the development, manufacturing, and distribution of a broad range of medical devices and therapies. The company operates worldwide, including in emerging markets, and serves healthcare providers, hospitals, and government healthcare systems. Medtronic's product portfolio includes devices for cardiovascular, diabetes, neurological, and surgical applications. The company invests in innovation and strategic acquisitions to expand its offerings, such as the recent $550 million acquisition of Scientia Vascular. Medtronic also focuses on digital health solutions, including AI-enabled tools and connected devices like the MiniMed Flex insulin pump. The company faces a complex regulatory environment, cybersecurity challenges, and pricing pressures from healthcare industry consolidation and managed care organizations. Medtronic pursues sustainability initiatives with targets for carbon neutrality and net zero emissions. Its financial position as of April 2026 reflects solid liquidity and profitability.

Honda Motor Co., Ltd. is a global manufacturer of motorcycles, automobiles, power products, and financial services headquartered in Tokyo, Japan. Founded in 1948, Honda has grown into a leading automotive and motorcycle company with diversified business segments. The company’s revenue streams are primarily derived from its motorcycle and automobile businesses, supplemented by financial services and power products. Honda operates worldwide with significant sales in North America, Japan, Asia, and Europe. The company pursues a long-term vision targeting zero environmental impact and zero traffic fatalities by 2050, balancing investments in internal combustion engine (ICE), hybrid, and electric vehicle (EV) technologies. Honda’s governance structure includes a Board of Directors with a majority of outside independent directors and a Risk Management Committee overseeing enterprise risks including cybersecurity.

Grace Therapeutics, Inc. develops and commercializes novel drug delivery formulations targeting rare and orphan diseases. The company applies proprietary technologies to reformulate approved pharmaceutical compounds, aiming to improve efficacy, safety, and patient compliance. Its pipeline includes three clinical-stage candidates, with GTx-104 as the lead product, an injectable nimodipine formulation for intravenous infusion in aSAH patients. The company leverages the FDA's 505(b)(2) regulatory pathway to potentially expedite approval. GTx-104 has demonstrated favorable safety and pharmacokinetic profiles in clinical trials and met primary endpoints in a Phase 3 safety trial. The company submitted an NDA for GTx-104, which was accepted but later received a CRL citing manufacturing and non-clinical data deficiencies. Grace Therapeutics relies on third-party contract manufacturing organizations and holds orphan drug designations for its candidates. Financially, the company has reported operating losses and maintains liquidity to support ongoing operations and potential NDA resubmission.

Accenture plc is a global professional services firm specializing in consulting, technology services, and managed services. It operates through three geographic segments: Americas, EMEA, and Asia Pacific, serving clients across diverse industries such as Communications, Media & Technology; Financial Services; Health & Public Service; Products; and Resources. The company’s business model focuses on helping clients accelerate digital transformation, leveraging cloud, AI, enterprise platforms, and security solutions. Accenture generates revenue primarily from consulting and managed services, with recent growth driven by demand for advanced AI and digital capabilities. The company maintains a strong liquidity position and returns capital to shareholders through dividends and share repurchases.

Starlink AI Acquisition Corp is a Cayman Islands exempted company that completed its IPO in May 2026 as a special purpose acquisition company (SPAC). The IPO raised approximately $100 million, with proceeds held in a trust account pending an initial business combination. The company has no reported revenue and incurred a net loss of $32,856 in the quarter ending April 30, 2026. It operates under the emerging growth company status and has a board including Chairman and CEO Gus Liu and independent directors Richard Lu and Xue Feng.

InnSuites Hospitality Trust is an Ohio real estate investment trust headquartered in Phoenix, Arizona, owning interests in two hotels located in Tucson, Arizona, and Albuquerque, New Mexico. The Trust operates these hotels through its majority-owned subsidiary, RRF Limited Liability Limited Partnership, which also manages an independent hotel services company. The hotels offer moderate-service accommodations with amenities such as pools, fitness centers, business centers, and dining options. The Trust's business model centers on generating returns through hotel operating income, asset appreciation, and diversification investments, including a stake in a clean energy company. The Trust's shares trade on the NYSE American under the symbol 'IHT'.

Earth Science Tech, Inc. operates through multiple subsidiaries including licensed compounding pharmacies (RxCompoundStore.com and Mister Meds), telemedicine platforms (Peaks Curative and DOConsultation.com), a brick-and-mortar healthcare facility (Las Villas Health Care), a real estate and asset management arm (Avenvi LLC), and a consumer products brand (MagneChef). The company emphasizes vertical integration to provide seamless patient care from consultation to medication fulfillment. It has expanded its licensure footprint to near-national coverage and focuses on fiscal discipline with significant insider ownership and a share repurchase program. Marketing strategies leverage digital channels and proprietary technology to drive patient acquisition and retention, while regulatory compliance spans pharmacy, telemedicine, consumer product safety, and advertising laws.

International Battery Metals Ltd. is a company engaged in the battery metals sector, with a particular emphasis on lithium production. The company has disclosed financial data through recent SEC filings, including a 10-Q report filed on February 25, 2026. It maintains strong liquidity with a current ratio of 7.64 and cash ratio of 6.63 as of March 31, 2026. The company reported a modest net income of $122,000 USD for the fiscal year ending March 31, 2026. Recent news highlights leadership changes and increased funding aimed at expanding lithium production capabilities.

Sony Group Corp is a diversified multinational conglomerate headquartered in Japan, operating across electronics, gaming, entertainment, and financial services sectors. The company files comprehensive annual and quarterly reports with the SEC, providing detailed financial and operational disclosures. Sony maintains active share repurchase programs and has recently completed significant treasury stock cancellations. The company faces industry-wide challenges such as memory shortages impacting the gaming segment and broader audio-video sector headwinds, while also pursuing strategic investments in music royalties and AI technologies.

DT Cloud Star Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in late 2022. Its business model is to identify and complete a merger or acquisition with a target company, thereby taking the target public. The company completed its IPO in July 2024, raising gross proceeds of $69 million, which are held in a trust account to fund the business combination. The management team, led by CEO Sam Zheng Sun, has extensive private equity and capital markets experience, focusing on sourcing and executing transactions with strong growth prospects and competitive advantages. The company entered into a definitive Business Combination Agreement in February 2026 with PrimeGen US, Inc., a biotech company, as the target. The business combination is subject to shareholder approval and closing conditions. The company’s financial position as of March 31, 2026, shows limited liquidity and a net loss for the quarter. The company faces a Nasdaq listing compliance risk due to insufficient public shareholders.

Kindcard, Inc. is a FinTech and PayTech company headquartered in Boca Raton, Florida, operating through two subsidiaries: Deb, Inc. and Tendercard, Inc. Deb, Inc. provides a global payment processing platform that supports traditional credit card, digital, and cryptocurrency transactions via partnerships with Blox and Viacarte, including the issuance of virtual and in-wallet Visa cards. Tendercard, Inc. offers a gift card and loyalty platform for merchants, enabling electronic gift card issuance and management with direct settlement to merchants. The company aims to grow its user base and merchant network by offering its platforms through resellers and software developers worldwide. Kindcard operates in a competitive payments industry dominated by major card issuers and seeks to provide a safer, cost-effective alternative payment solution. The company complies with relevant government regulations and maintains intellectual property through trade secrets and trademarks. As of April 2026, Kindcard reported revenue of $74.2 million and a net loss of $62.4 million, with liquidity ratios indicating low short-term asset coverage of liabilities [S1][S2].

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Boston, Massachusetts. The company completed its initial public offering in May 2026 and is listed on The Nasdaq Stock Market under the ticker ODTX. It has executed a private placement financing concurrently with the IPO. The company reported a net loss for the quarter ended March 31, 2026, and maintains a strong liquidity position with significant cash, short-term investments, and current assets relative to current liabilities. Specific details about its product pipeline, therapeutic focus, or commercial activities are not disclosed in the available SEC filings or public news sources.

Skkynet Cloud Systems, Inc. is a technology company incorporated in Nevada with principal executive offices in Mississauga, Ontario, Canada. The company has publicly filed annual and quarterly reports with the SEC, providing financial data and risk disclosures. Its recent financials show quarterly revenue of approximately $606,000 and a net loss of about $109,000 as of April 30, 2026. The company maintains liquidity with a current ratio above 2.0. In late 2025, Skkynet announced an Industrial AI Product Development Initiative partially funded by the Canadian government, indicating a focus on AI-related technology development. Public news coverage is primarily commodity market related and does not provide direct insight into the company's business model or industry classification.

Smith & Wesson Brands, Inc. designs, manufactures, and markets firearms and related products under the Smith & Wesson and Gemtech brands. The company serves a broad customer base including distributors, law enforcement agencies, government and military entities, businesses, retailers, and retail consumers globally. The company’s fiscal 2026 net sales increased 10.4% to $523.8 million, driven by higher sales volume. Operating income rose to $29.2 million, supported by improved gross margins and controlled expenses. The company is subject to extensive regulation and faces demand volatility influenced by political, social, and economic factors. It continues to invest in new product development and has expanded its direct-to-consumer e-commerce platform for apparel and firearm accessories. The company maintains a strong liquidity position with $28.2 million in cash and a current ratio of 3.2 as of April 30, 2026. Risks include regulatory changes, supply chain constraints, product liability, cybersecurity threats, and competitive pressures.

Satellogic Inc. is a Delaware-incorporated company engaged in satellite production and Earth observation services. It operates as an emerging growth and smaller reporting company, with shares traded on the Nasdaq Capital Market. The company is focused on building its Merlin satellite constellation and expanding commercial operations. It has entered into agreements to raise capital through share offerings and has extended contracts for satellite imagery services with government clients. The company reported a net loss in Q1 2026 but maintains a strong liquidity position with over $120 million in cash and equivalents. Operational cash flow has improved recently, and investing activities reflect increased satellite production. The company is subject to typical risks of emerging space technology firms, including capital requirements and market competition.

Charlton Aria Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands. Its business model is to raise capital through an IPO and private placements, hold the proceeds in a trust account, and seek to complete an initial business combination with one or more target businesses. The company has no operating history or revenue and is classified as a shell company. It completed its IPO in October 2024, raising $75 million, and has since been evaluating potential acquisition targets without industry or geographic limitations. The company must complete its initial business combination by July 25, 2026, following extensions funded by the sponsor. The post-transaction company is expected to own a controlling interest in the target business. The company faces competition from other SPACs and acquisition entities. It has undergone recent management changes and is currently addressing Nasdaq compliance issues related to late filings.

Satellogic Inc. operates in the satellite and earth observation sector, providing high-resolution satellite imagery and analytics services. The company is publicly traded on Nasdaq under the ticker SATL and has issued warrants under SATLW. It is incorporated in Delaware and classified as an emerging growth and smaller reporting company. Satellogic has engaged in capital markets activities including registered direct offerings and a sales agreement to raise up to $50 million of common stock. The company has secured multi-million dollar contracts for satellite imagery services in regions including Asia Pacific and has extended monitoring agreements with governments such as Albania. Financially, the company reported a net loss in Q1 2026 but maintains a strong liquidity position with over $120 million in cash and equivalents and a current ratio above 2. The company’s business model centers on satellite data acquisition and analytics, serving government and commercial clients.

Innovative Designs Inc is a smaller reporting company focused on manufacturing and selling cold weather apparel under the Arctic Armor line and House Wrap products. The company emphasizes product features such as lightweight, waterproof, windproof, sub-zero protection, and buoyancy, leveraging its proprietary Insultex material which has been tested for gas permeation resistance. Sales are primarily concentrated in colder regions of the United States and Canada. The company markets its products through a combination of online presence, professional sales representatives, distributors, and manufacturer representatives targeting retailers, contractors, and end users. The business faces significant competition from established companies with greater brand recognition and resources. The company is dependent on a single supplier for its key Insultex material and a single manufacturer in Indonesia for apparel production. Seasonal weather conditions influence sales cyclicality, particularly for the Arctic Armor line.

Four Seasons Education (Cayman) Inc. is a Cayman Islands incorporated company that operates in the education sector, with its principal executive offices located in Shanghai, PRC. The company files annual reports on Form 20-F with the SEC and is listed on the NYSE. It reported net income and liquidity metrics as of February 28, 2026, and is subject to tax regulations in the Cayman Islands, PRC, and the United States. The company is classified as a Passive Foreign Investment Company for U.S. tax purposes, which has implications for U.S. investors.

Founded in 2013, Oklo Inc. develops next-generation fast fission power plants called Aurora powerhouses, designed to produce 15 to 75 megawatts electric (MWe) using fast neutron technology demonstrated by the Experimental Breeder Reactor-II. The Aurora powerhouses can operate on fresh, recycled, or down-blended nuclear fuel, tapping into the vast energy reserves in used nuclear fuel. Oklo's business model involves building, owning, and operating these powerhouses and selling electricity and heat directly to customers through power purchase agreements, enabling recurring revenue and operational control. The company is also commercializing advanced nuclear fuel recycling and fuel fabrication technologies, aiming to deploy a commercial-scale recycling facility in the U.S. by the early 2030s. Oklo has secured regulatory milestones including site use permits at Idaho National Laboratory, DOE approvals of safety design documents, and has a growing pipeline of customer agreements including a 12 GW Master Power Agreement with Switch and a prepayment agreement with Meta Platforms. The company acquired Atomic Alchemy to expand into radioisotope production. Oklo reported a net loss and continues to invest heavily in R&D and operations, supported by a strong liquidity position. The company faces risks from supply chain vulnerabilities, inflation, trade policies, regulatory challenges, and competition in the advanced nuclear and energy markets.

JFB Construction Holdings operates as a holding company for its wholly owned subsidiary, JFB Construction & Development Inc., providing commercial and residential construction and real estate development services. The company’s commercial segment includes franchise buildouts and general commercial construction, with projects completed in 36 states and a strong presence in the Southern Atlantic region. The residential segment focuses on custom homes and luxury equestrian facilities primarily in South Florida. The real estate development segment involves low-rise apartment and townhouse projects, with plans for future investments and joint ventures. JFB emphasizes quality craftsmanship, operational flexibility, and long-term client relationships, particularly within the franchise industry. The company’s growth strategy targets expansion in states with population and economic growth, including Florida, Texas, and South Carolina, while managing risks related to competition, cost inflation, and project execution.

Takeda Pharmaceutical Co Ltd is a Japan-headquartered global biopharmaceutical company focused on discovering and delivering treatments across multiple therapeutic areas including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company operates in approximately 80 countries and regions and emphasizes values-based management and R&D innovation. Takeda's business model centers on advancing a dynamic and diverse pipeline through clinical development, regulatory approvals, and commercialization. Recent clinical milestones include positive Phase 3 data for Oveporexton in narcolepsy and regulatory submissions for ENTYVIO IV in pediatric inflammatory bowel diseases. The company also manages legal contingencies and pursues enterprise-wide efficiency programs to enhance profitability and operational agility.

Vynleads, Inc. operates a digital wellness platform focused on metabolic health, primarily through its Done With Diabetes app, an eight-week structured program designed to support adults with type 2 diabetes and related conditions. The platform integrates AI-driven personalization, including the Dr. Smith AI Coach and agentic AI workflows, to deliver daily missions, educational content, meal guidance, and community engagement. The company shifted its strategy in 2026 to emphasize a subscription-based model priced at $29 per month after a free trial, aiming to build recurring revenue and user engagement. Vynleads also plans to expand its platform to additional chronic conditions and pursue enterprise partnerships with employers, health plans, and other stakeholders. The company relies on a cloud-based infrastructure and third-party services to support its technology and operations. Competition is significant, with many larger players in digital health and wellness markets. Regulatory and compliance considerations are important given the health-related nature of the offerings. As of early 2026, the company had one employee and depends heavily on external partners for development and support.

TRANSUITE.ORG INC. operates in the technology and consulting sector with a focus on AI-driven ecosystem product planning and online medical education through its subsidiaries. The company is engaged in strategic expansion into Web3 technologies, digital asset trading platforms, and financial infrastructure through partnerships and acquisitions. It has a history of net losses and significant non-cash operating expenses related to stock-based compensation and goodwill impairment. The company is actively managing its capital structure and liquidity while pursuing growth opportunities in emerging digital financial ecosystems.

Aimei Health Technology Co., Ltd. is a Cayman Islands exempted company formed as a SPAC to identify and complete a business combination with a healthcare innovation company. The company targets small-cap firms in biopharmaceuticals, medical technology/devices, and diagnostics across North America, Europe, and Asia Pacific. Since its IPO in December 2023, the company has not commenced operations or generated operating revenue. Its activities have been limited to organizational matters, IPO-related costs, and pursuit of a business combination. Income is derived from interest on cash held in trust from IPO proceeds. The company has extended the deadline to consummate a business combination multiple times, with the latest extension to July 6, 2026. The company has a working capital deficit and material weaknesses in internal controls, with plans to remediate. Insider share sales have occurred.

NovaBridge Biosciences, formerly known as I-Mab, is a biotechnology platform company engaged in the research, development, and commercialization of innovative medicines primarily in oncology and ophthalmology. The company operates through subsidiaries including Visara Inc., focused on ophthalmology, and has divested its China-based operations under TJ Biopharma. Its pipeline includes multiple clinical-stage drug candidates such as givastomig, a bispecific antibody targeting gastric cancer, and VIS-101 for wet age-related macular degeneration. NovaBridge has established strategic collaborations, including a global partnership with AbbVie for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody. The company recognizes revenue from licensing, collaboration agreements, and milestone payments, applying ASC 606 standards. It maintains a strong cash position and liquidity to support ongoing clinical development and operational activities.

Pulmatrix, Inc. is a Delaware-based biopharmaceutical company focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ dry powder delivery platform. This technology enables efficient delivery of small, dense particles to the airways and can be formulated with various drug substances and inhaler devices. The company’s historical revenue was primarily derived from a collaboration and license agreement related to PUR1900 under the Cipla Agreement, but no revenue was recognized in 2025. Pulmatrix has entered into strategic merger agreements with Cullgen Inc. and Eos Senolytix to expand its therapeutic pipeline and capabilities. The company has a history of recurring losses and reported a net loss of $1.17 million for Q1 2026. As of March 31, 2026, Pulmatrix held $3.32 million in cash and cash equivalents, with a current ratio of 4.96, indicating strong liquidity. The company’s future operations depend on successful capital raises and the consummation of the proposed mergers. Risks include the ability to raise capital, geopolitical instability, and the challenges of commercializing new therapies.

La-Z-Boy Inc is a company with publicly disclosed financials and governance structures. The company reported revenues of approximately $2.35 billion for fiscal year 2023 and net income of about $102 million for fiscal year 2026. It maintains liquidity with a current ratio of 1.8 and cash ratio of 0.71 as of April 25, 2026. The company has a dedicated cybersecurity leadership team reporting to executive management and the Board. Recent public coverage includes earnings call transcripts, dividend announcements, and analysis of earnings and stock price movements.

VRXA is a publicly traded company with minimal publicly disclosed information about its business model, sector, or financial performance. The company’s share price was $9.40 as of mid-June 2026. There is no available data on revenue, net income, or other financial metrics. Recent news indicates the company is entering a new chapter, implying some form of strategic or operational change, though specifics are not provided.

Sonoma Pharmaceuticals, Inc. is a pharmaceutical company specializing in Microcyn® technology-based products. The company operates primarily in the United States and has entered into a manufacturing and supply agreement with Kenvue Brands LLC for the sale of these products. Sonoma is publicly traded on Nasdaq under the ticker SNOA. The company has recently engaged in capital raising activities through a public offering involving common stock and warrants. Financial disclosures indicate revenues of approximately $19.5 million for the fiscal year ended March 31, 2026, with a net loss of $3.18 million. Sonoma maintains a current ratio of 2.5, reflecting liquidity above current liabilities. The company has also transitioned some products to comply with new EU Medical Device Regulation (MDR) requirements. Risk factors have remained consistent with prior disclosures.

LAMY, incorporated in Wyoming in 2022, operates in the eLearning and gaming sectors with a focus on teaching financial knowledge and resource management to children. Its primary product is the twoplus1® video game, which offers an immersive educational experience in finance and real estate through a subscription model and includes features for virtual property trading to generate commissions. The company underwent a change in control in late 2024, with new leadership appointed. LAMY has trademark protections for its brand and is expanding its business through strategic acquisitions, notably acquiring Exousia AI, a cancer therapy innovator, in 2025. The company also engages in partnerships related to financial literacy initiatives and green energy projects involving NFTs and metaverse technologies. Financially, LAMY reported no revenue and a net loss in the latest quarter, with significant assets related to its acquisition and ongoing research and development expenses. The company is classified as a smaller reporting and emerging growth company and plans to raise additional capital to support its operations and growth.

Pacific Booker Minerals Inc. is a mineral exploration company incorporated in British Columbia, Canada, with all operations and assets located in Canada. The company focuses on the Morrison copper/gold project, which it acquired through option and purchase agreements with Noranda and its successors. The Morrison project has undergone extensive exploration, feasibility studies, and environmental assessments. The company completed a full feasibility study in 2009 describing an open pit mine with a 30,000 tonnes per day mill. However, the company has faced regulatory challenges, including denial of Environmental Assessment Certificates by British Columbia authorities in 2012 and 2022, leading to legal challenges and ongoing efforts to redesign the project and reapply. The company engages with First Nations groups, including the Lake Babine Nation, with mixed communication outcomes. The company has no subsidiaries and leases office space in Vancouver. It has no operating revenue and relies on interest income and equity financing to fund its activities. The company’s financial position as of January 31, 2026 shows a working capital deficit and net losses. The company is conducting a strategic review and technical assessment of the Morrison project and has announced a private placement to raise funds for development and strategic initiatives [S1].

Nobility Homes Inc specializes in the design, production, and sale of affordable manufactured and modular homes, primarily serving the Florida market. The company operates multiple retail sales centers and sells homes both directly to consumers and through independent dealers and manufactured home parks. It also operates an insurance agency subsidiary generating commission revenues. The company is the only vertically integrated manufactured home company headquartered in Florida and has been in business for 59 years as of 2026. The business model includes manufacturing homes at its own facilities and retailing them through its sales centers, with a focus on affordable housing solutions. The company’s financial performance is influenced by housing market conditions, interest rates, and supply chain factors.

Stark Focus Group, Inc. was incorporated in Nevada in 2018 and initially operated through its wholly owned subsidiary, Common Design Limited, a Hong Kong-based wholesale clothing supplier specializing in niche apparel for global markets. The company sold this subsidiary in 2021. In 2022, Stark Focus Group announced its entry into the drone and unmanned aerial vehicle market under the brand RevoluDrones, aiming to commercialize drone models through its website and select retail channels. As of the latest filings, the company has not generated revenues and is pursuing various business opportunities to establish active operations. Financially, the company reported net losses and a working capital deficiency, with no cash on hand as of March 31, 2026 [S1][S2].